Compare GFL Environmental Inc. Subordinate voting shares no par value (GFL) vs Maravai LifeSciences Holdings Inc. Class A Common Stock (MRVI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GFL Environmental Inc. Subordinate voting shares no par value vs Maravai LifeSciences Holdings Inc. Class A Common Stock — how do they compare? GFL Environmental Inc. Subordinate voting shares no par value trades at $42.95 (market cap $18.64B), while Maravai LifeSciences Holdings Inc. Class A Common Stock trades at $6.56 (market cap $972.90M). The key difference: GFL Environmental Inc. Subordinate voting shares no par value is far larger — about 19.2× Maravai LifeSciences Holdings Inc. Class A Common Stock's market cap, and GFL Environmental Inc. Subordinate voting shares no par value pays a 0.16% dividend while Maravai LifeSciences Holdings Inc. Class A Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold GFL Environmental Inc. Subordinate voting shares no par value for 6 Days and Maravai LifeSciences Holdings Inc. Class A Common Stock for 0 Days on average.
| GFL | MRVI | |
|---|---|---|
Market Cap | $18.64B | $972.90M |
Volume | 2,514,524 | 4,325,710 |
Sector | Industrials | Health |
52-Week High | $46.51 | $9.00 |
52-Week Low | $33.54 | $2.83 |
Typical Hold Time | 6 Days | 0 Days |
Enterprise Value | $25.61B | $1.08B |
Dividend Yield | 0.16% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GFL trades at $42.75, up 0.87% today, with a bullish technical signal from moving averages. Recent Q2 2026 earnings missed estimates, but the company raised full-year 2026 guidance. Revenue is projected to grow to $7.0B in 2026, though net income is expected to turn negative. The company recently acquired SECURE Waste Infrastructure and announced a quarterly dividend, signaling financial activity.
Outlook is mixed: strong analyst buy consensus (77.8%) and positive news flow support upside, but negative profit margins and high valuation ratios pose risks. The stock's performance hinges on execution of growth initiatives and margin improvement in a competitive industrial sector.
Maravai LifeSciences (MRVI) trades at $6.53, down 7.51% in the last session amid mixed signals. The stock shows improving fundamentals with Q2 2026 revenue growth of 9% and three consecutive earnings beats, though it remains unprofitable with a -37.07% net margin. Technical analysis indicates neutral positioning with key support at $6 and resistance at $7. Recent news highlights patent expansions in China and institutional accumulation.
The outlook remains cautiously optimistic with analyst consensus pointing to 7% upside potential to the $7.00 price target. Key opportunities include margin expansion and RNA technology leadership, while risks center on persistent cash burn and competitive pressures in life sciences. The stock offers speculative growth potential for risk-tolerant investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About GFL Environmental Inc. Subordinate voting shares no par value
GFL Environmental provides environmental services across Canada and the United States. Its operations include solid waste management and other waste and environmental solutions.
Read more on GFL →About Maravai LifeSciences Holdings Inc. Class A Common Stock
Maravai LifeSciences Holdings Inc. is a life sciences company supporting drug therapy, diagnostic, and vaccine development through four operating brands: TriLink BioTechnologies (nucleic acid and mRNA synthesis), Cygnus Technologies (biologics safety testing), Glen Research (oligonucleotide synthesis materials), and Alphazyme (enzyme manufacturing). It serves biotech and biopharma customers from discovery through commercial manufacturing.
Read more on MRVI →
